SCHEMBL6978635

SCHEMBL6978635

CCOC(=O)c1cnc2c3c(ccc2c1Cl)C(=O)C(C(C)=O)C=N3

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.53
MEN1 O00255 2/20 0.53
ALDH1A1 P00352 4/20 0.41
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 5/20 0.39
POLB P06746 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
PKM P14618 1/20 0.38
THRB P10828 1/20 0.38
TP53 P04637 1/20 0.38
KDM4E B2RXH2 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HPGD P15428 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7798795 0.82 KMT2A (0.39) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL538007 0.71 KMT2A (0.65) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL3803998 0.70 KMT2A (0.64) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL31276019 0.70 KMT2A (0.64) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL2017369 0.70 KMT2A (0.71) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL2020438 0.70 KMT2A (0.71) KMT2AMEN1ALDH1A1LMNAMAPK1
SCHEMBL2021129 0.70 KMT2A (0.63) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL18285392 0.70 MEN1 (0.63) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL2021172 0.69 KMT2A (0.70) KMT2AMEN1ALDH1A1LMNAUSP2
SCHEMBL18987613 0.69 MEN1 (0.62) KMT2AMEN1ALDH1A1LMNAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP claimed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP claimed
WO-1999021860-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 1999-08-05 WO claimed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO claimed
EP-1027351-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 2003-12-03 EP disclosed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
US-6200974-B1 FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT ZENECA LIMITED (GB) 2001-03-13 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 KMT2A 1250/4885MEN1 2187/4885ALDH1A1 425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.